A germline deletion of p14ARF but not CDKN2A in a melanoma–neural system tumour syndrome family
JA Randerson-Moor, M Harland… - Human molecular …, 2001 - academic.oup.com
JA Randerson-Moor, M Harland, S Williams, D Cuthbert-Heavens, E Sheridan, J Aveyard…
Human molecular genetics, 2001•academic.oup.comThe melanoma–astrocytoma syndrome is characterized by a dual predisposition to
melanoma and neural system tumours, commonly astrocytoma. Germline deletions of the
region on 9p21 containing the CDKN2A and CDKN2B genes and CDKN2A exon 1β have
been reported in kindreds, implicating contiguous tumour suppressor gene deletion as a
cause of this syndrome. We describe a family characterized by multiple melanoma and
neural cell tumours segregating with a germline deletion of the p14ARF-specific exon 1β of …
melanoma and neural system tumours, commonly astrocytoma. Germline deletions of the
region on 9p21 containing the CDKN2A and CDKN2B genes and CDKN2A exon 1β have
been reported in kindreds, implicating contiguous tumour suppressor gene deletion as a
cause of this syndrome. We describe a family characterized by multiple melanoma and
neural cell tumours segregating with a germline deletion of the p14ARF-specific exon 1β of …
Abstract
The melanoma–astrocytoma syndrome is characterized by a dual predisposition to melanoma and neural system tumours, commonly astrocytoma. Germline deletions of the region on 9p21 containing the CDKN2A and CDKN2B genes and CDKN2A exon 1β have been reported in kindreds, implicating contiguous tumour suppressor gene deletion as a cause of this syndrome. We describe a family characterized by multiple melanoma and neural cell tumours segregating with a germline deletion of the p14ARF-specific exon 1β of the CDKN2A gene. This deletion does not affect the coding or minimal promoter sequences of either the CDKN2A or CDKN2B genes. Our results are consistent with either: (i) loss of p14ARF function being the critical abnormality associated with this syndrome, rather than contiguous loss of both the CDKN2A and CDKN2B genes as suggested previously; or (ii) disruption of expression of p16 by mechanisms as yet unknown.
Oxford University Press